Aggarwal, R. R., Vuky, J., VanderWeele, D. J., Rettig, M., Heath, E. I., Beer, T. M., … Small, E. J. (2022). Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). In JOURNAL OF CLINICAL ONCOLOGY (Vol. 40).

Aggarwal, Rahul Raj, Jacqueline Vuky, David James VanderWeele, Matthew Rettig, Elisabeth I. Heath, Tomasz M. Beer, Jiaoti Huang, et al. “Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 40, 2022.

Aggarwal RR, Vuky J, VanderWeele DJ, Rettig M, Heath EI, Beer TM, et al. Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). In: JOURNAL OF CLINICAL ONCOLOGY. 2022.

Aggarwal, Rahul Raj, et al. “Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC).” JOURNAL OF CLINICAL ONCOLOGY, vol. 40, no. 16, 2022.

Aggarwal RR, Vuky J, VanderWeele DJ, Rettig M, Heath EI, Beer TM, Huang J, Pawlowska N, Sinit R, Abbey J, Liu B, Nasoff M, Dorr A, Small EJ. Phase 1a/1b study of FOR46, an antibody drug conjugate (ADC), targeting CD46 in metastatic castration-resistant prostate cancer (mCRPC). JOURNAL OF CLINICAL ONCOLOGY. 2022.